Entheon Biomedical
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Entheon Biomedical Corp. (CSE: ENBI, OTCQB: ENTBF) was a biotechnology research and development company developing DMT-based psychedelic therapeutic products for treating addiction and substance use disorders. Led by CEO Timothy Ko, it organized around three divisions — Entheon RX (DMT drug development), Entheon ID (EEG biomarkers and genetics for patient selection), and Entheon IQ (treatment algorithms from patient data) — and launched HaluGen, a direct-to-consumer genetic test kit assessing psychiatric risk factors for psychedelic therapies.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Psychedelic ETF inclusion
Entheon was included in the first North American psychedelic ETF (Horizons Psychedelic Stock Index ETF), gaining liquidity and visibility.
- Partnerships and supply
Entheon partnered with Divergence Neuro Technologies for a predictive biomarker platform and entered a DMT supply agreement with Psygen for preclinical and clinical trials.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.